In recent years, drug discovery has advanced rapidly to yield increasingly sophisticated medicines, yet our primary method of administering these drugs remains remarkably unchanged. Many of these new and advanced macromolecules still rely on standard liquid injections, a dependence that imposes a significant physical and financial burden on patients and healthcare systems alike. Liquid injections frequently require cold-chain transport, clinic visits, administration by trained professionals and the physical discomfort of a needle.
The Legacy of Liquid Injection Biologics now represent approximately 40% of the global drug development pipeline and account for nearly half of all new drug approvals.1 These complex macromolecular therapies are transforming treatment across chronic therapeutic areas, including autoimmune diseases, cancers, endocrine disorders and genetic conditions. Despite their therapeutic promise, these complex structures cannot survive oral administration, as gastric enzymes and the acidic environment of the stomach degrade the molecules before they can enter the bloodstream.
The Legacy of Liquid Injection Biologics now represent approximately 40% of the global drug development pipeline and account for nearly half of all new drug approvals.1 These complex macromolecular therapies are transforming treatment across chronic therapeutic areas, including autoimmune diseases, cancers, endocrine disorders and genetic conditions. Despite their therapeutic promise, these complex structures cannot survive oral administration, as gastric enzymes and the acidic environment of the stomach degrade the molecules before they can enter the bloodstream.2
While bypassing this gastric barrier has long made liquid subcutaneous or intramuscular injections the default pathway for systemic biologic delivery, this approach carries physical and logistical challenges:
- Clinic visits require travel, consume patient time and increase the overall cost of care.
- Self-injection demands a high degree of manual dexterity and patient training.
Beyond these administration challenges, liquid formulations often present significant shelf-life limitations due to their molecular instability at room temperature. These formulations remain highly vulnerable to thermal fluctuations, light and mechanical stress. This sensitivity necessitates a continuous cold chain from manufacture to administration, which limits medicine distribution in developing regions, increases carbon footprints and generates substantial waste when temperatures slip outside of safe limits.
